68K shares changed hands by the end of trading on Tuesday. Trading volume was up 618.41% over the stocks average daily volume.
Investors are a little more bullish recently at least if you consider the downtick in short interest. The firm had a fall in short interest of -6.43% between September 29, 2017 and October 13, 2017. Short shares fell 2,341 over that period. With short interest at 34,092 and short average daily volume at 5,938, days to cover is 6.0 and the percentage of shorted shares was 0.00% on October 13.
Here are a few substantial investment firms who have updated their positions. Tower Research Capital LLC (trc) trimmed its investment by shedding 464 shares a decrease of 82.3%. Tower Research Capital LLC (trc) now controls 100 shares valued at $1,000. The total value of its holdings decreased 80.0%. Acadian Asset Management LLC expanded its stake by buying 8 shares an increase of 0.4% in the quarter. Acadian Asset Management LLC controls 2,153 shares worth $23,000. The value of the position overall is up by 9.5%.
As of quarter end Wells Fargo & Company/mn had bought 8,700 shares growing its position 4.7%. The value of the investment in (NAII) increased from $1,856,000 to $2,108,000 a change of $252,000 quarter to quarter. As of the end of the quarter Dimensional Fund Advisors Lp had acquired a total of 8,685 shares growing its holdings by 1.6%. The value of the company’s investment in Natural Alternativ went from $5,421,000 to $5,866,000 increasing 8.2% since the last quarter.
The company is so far trading up by 1.00% percent from yesterday’s close. The company’s P/E ratio is 9.35 and the market cap of the company is 75.40M. In the last earnings report the EPS was $1.09 with 7.43M shares currently outstanding.
Natural Alternatives International, Inc., launched on October 26, 1989, is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through three segments: private-label contract manufacturing, patent and trademark licensing, and branded products. The private-label contract manufacturing segment primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other healthcare products. The patent and trademark licensing segment primarily includes direct raw material sales and royalty income from its license and supply agreements associated with the sale and use of beta-alanine under its CarnosSyn trade name. The branded products segment relates to the marketing and distribution of branded nutritional supplements and consists primarily of the products sold under its Pathway to Healing product line..